Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2011

View Archived Issues

Archaeosome-encapsulated RD T-cell antigen vaccine efficacious against experimental tuberculosis

Herceptin conjugates induce programmed necrotic tumor cell death

Diamyd to concentrate resources on pain portfolio

Eisai enrolls participants in phase III rufinamide study

Cytos Biotechnology to focus on lead product

Verona Pharma reports data from phase II RPL-554 trial

Emergent BioSolutions begins trial of TRU-016 in relapsed, indolent lymphoma

Allos Therapeutics begins phase III registration trial of Folotyn

First Ultragenyx product enters clinical development

New GPR52 receptor agonists prepared by Takeda

Researchers at Pfizer disclose new gamma-secretase modulators

Lexicon Pharmaceuticals reports phase II data on telotristat etiprate

Nippon Chemiphar presents new GPR119 receptor agonists

Scientists at Vertex design novel PKC-theta inhibitors

Sanofi synthesizes novel fatty-acid amide hydrolase 1 inhibitors

New prodrugs of proteasome inhibitors designed by Cephalon

Roche obtains FDA approval for melanoma drug and companion diagnostic

FDA approves Intersect ENT's Propel implant

Gentium withdraws defibrotide NDA

Dual FGF/VEGF pathway inhibitor shows promise in limiting tumor resistance to VEGF inhibition

FDA accepts for review Protalix Biotherapeutics' resubmitted NDA for taliglucerase alfa

New approval for Progensa PCA3 test

Zogenix's phase III trial of Zohydro meets primary endpoint

Paladin Labs to acquire Labopharm

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...